CorMedix Is Announcing Preliminary Net Revenue Guidance For First Half Of 2025 Of $50M–$60M
Benzinga
03-25
CorMedix is announcing preliminary net revenue guidance for first half of 2025 of $50 – $60 million, based on the run rate of current purchasing customers, with more than $33 million expected in first quarter. In addition, the Company reiterates its previously announced cash operating expense guidance for 2025 of $72 – $78 million.